Naoxintong capsule, as its name implies, is the representative of the theory of "treating both brain and heart", which can be used for the secondary prevention of stable angina pectoris (caused by coronary artery occlusion and stenosis), unstable angina pectoris (caused by coronary artery spasm) and myocardial infarction. The so-called secondary prevention means that these diseases already exist, in order to prevent their recurrence.
It can also be used for transient ischemic attack, cerebral infarction (including acute stage, recovery stage and sequela stage), channels and collaterals in stroke, and sequela of stroke (accompanied by hemiplegia, numbness of limbs, mouth and eyes askew and strong tongue).
Modern pharmacological research shows that Naoxintong plays a corresponding role mainly through four aspects. Anti-thrombosis, anti-inflammation, anti-oxidation, regulating blood lipid metabolism and stabilizing plaque, and inhibiting the remodeling of organs such as blood vessels and heart.
Anti-thrombosis is mainly reflected in regulating the expression of tumor necrosis factor, vascular endothelial growth factor and P- selectin, thus inhibiting thrombosis, inhibiting platelet aggregation rate, prolonging coagulation time and improving blood hypercoagulability. At the same time, the antithrombotic effect of clopidogrel, an antiplatelet drug, can be improved by increasing the liver drug enzyme of P450CYP2C 19 genotype, because clopidogrel can only play its role through the metabolism of liver drug enzyme of this genotype.
Anti-inflammatory and anti-oxidation are mainly reflected in reducing carotid plaque, reducing carotid intima thickness, delaying plaque progress and preventing thrombosis through anti-inflammation. In addition, by reducing leukocyte infiltration, the inflammatory reaction caused by ischemia-reperfusion injury is inhibited, the disorder of cell energy metabolism is improved, and brain tissue is protected.
Inhibition of vascular and cardiac remodeling is mainly reflected in inhibition of carotid intima thickening, reduction and stabilization of plaque, improvement of blood flow parameters, delay of vascular remodeling, inhibition of myocardial cell hypertrophy through autophagy, promotion of angiogenesis and repair of myocardial infarction.
Many clinical trials of Naoxintong in treating cerebral infarction and carotid atherosclerosis show that compared with routine treatment, Naoxintong group can further optimize blood lipid metabolism and improve related indexes.
For high-risk elderly patients with nonvalvular atrial fibrillation, aspirin combined with Naoxintong is similar to warfarin in preventing ischemic stroke and all-cause mortality, and can significantly reduce the incidence of bleeding.
Patients after cardiac stent implantation often need to take clopidogrel, an antiplatelet drug. Naoxintong can significantly improve clopidogrel resistance and reduce cardiovascular events.
Tongxinluo is a representative Chinese patent medicine developed under the guidance of collateral disease theory. Has the effects of expelling pathogenic wind and dredging collaterals, and can be used for coronary heart disease, angina pectoris, acute myocardial infarction and ischemic stroke.
Modern pharmacological research shows that Tongxinluo also achieves the purpose of treating cardiovascular diseases mainly through four aspects. Including protecting vascular endothelial function, anti-inflammatory and anti-oxidation, regulating blood lipid metabolism and stabilizing plaque, inhibiting vascular and ventricular remodeling.
The function of protecting vascular endothelium is mainly embodied in regulating vascular endothelial function, inhibiting the interaction between white blood cells and endothelial cells, and relieving the microcirculation disturbance of the brain.
Anti-inflammatory and anti-oxidation are mainly reflected in reducing oxidative stress and inflammatory reaction of vascular endothelial cells and improving atherosclerotic lesions.
Regulating blood lipid metabolism and stabilizing plaque mainly inhibit the progress of atherosclerosis through various mechanisms to achieve the effect of stabilizing plaque.
The inhibition of vascular and ventricular remodeling is reflected in inhibiting vascular inflammation and intimal hyperplasia, promoting the formation of new blood vessels, improving heart function and cardiac remodeling.
For patients after cardiac stent implantation, clopidogrel+Tongxinluo can significantly improve the resistance of clopidogrel, and the curative effect is equivalent to twice the dose of clopidogrel.
For patients with coronary heart disease, routine treatment plus Tongxinluo can obviously relieve the symptoms of angina pectoris and reverse the abnormal ECG.
For patients with carotid plaque, routine treatment plus Tongxinluo treatment for 2 years can safely and effectively reduce carotid intima-media thickness, plaque area and vascular remodeling index, reduce major cardiovascular events and greatly reduce the incidence of angina pectoris.